Markets
ALX Oncology Stock Plunges 11% After Earnings — Its Quarterly Loss Narrows
The shares were on pace for their third drop of 10% or more this month, with breast-cancer results expected in 2027.
ALX Oncology Holdings (ALXO) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
The shares were on pace for their third drop of 10% or more this month, with breast-cancer results expected in 2027.
SEC Filings
Breast-cancer trial results are expected in the second half of 2027; an earlier solid-tumor readout is due in December.
SEC Filings
Corey Goodman's group still reports 9.99% of ALX Oncology after the exchange, and its amended filing states no new demands.
SEC Filings
Funds tied to Blackstone Annex Master Fund account for most of the stock being traded in for warrants with a $0.001 exercise price.